Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.
- GenAI: The Muscle Behind Strong Regulatory Intelligence For Combination Products
- Regulatory Precedents For Drug Delivery: Uncovering Clues To Successful Submissions
- Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage
- Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational Success
- Rethinking Product Development Through Lipid-Based Formulations
- Overcoming Lung Tumor Barriers: Nanoparticle Delivery Strategies For Pulmonary Cancers
- Advances In Endometrial-Targeted Drug Delivery In Women's Health
- RNA Delivery Technologies: Industrial Applications And Emerging Innovations
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Insights Into Drug Delivery Device Manufacturing From Development Through Commercialization
Biologics and other targeted therapy techniques are creating opportunities for innovative device solutions that meet the needs of specific patient groups. As these therapies often require low annual volumes, the associated device manufacturing strategy must also fit commercial expectations, even at those volumes.
-
Seven Softgel Myths: Are You Missing Your Softgel Opportunity?
Softgels are a popular dose format among consumers, thanks to their high swallowability and quick onset of action, yet pharmaceutical developers may not even consider them. Why the disconnect?
-
A Pathway For Regulatory Success For Devices In Combination Products
Ready to improve your submission success rate? Define clear submission goals, ensure cross-functional collaboration, and proactively manage evolving regulations to achieve a successful path to market.
-
Factors To Consider When Selecting A CDMO For Complex Injectables Development And Manufacture
The right CDMO partner will have specialized technologies for complex injectable development along with the equipment, facilities and operations to adopt GMP practices with a "laboratory setting."
-
Delivering Macromolecules: Challenges Associated With The Delivery Of Biologic Drugs
Developers need to look beyond the formulation of a stable drug all the way to patient compliance. Numerous pitfalls exist along the journey to bring a biologic combination product to market. This integrated solutions program can help you simplify the journey.
-
5 Ways Pre-Filled Syringes Contribute To Better Patient Outcomes
In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.
-
New Polymer Overcomes Limits In Sustained Drug Delivery In Ophthalmology
Challenges specific to eye physiology complicate the development of new therapies and necessitate innovative drug delivery methods. Biodegradable polymers show promise in addressing these challenges.
-
Overcoming Manufacturing Challenges For Accelerated Drug Development
Expedited development programs require adapting to accelerated development timelines. The challenge is to build a strategy that maintains the integrity, quality, and timeliness of the manufacturing process.
-
A Custom Pill For Every Patient
By enabling the creation of personalized medications and offering a wider range of products, 3D printing technology has the potential to enhance patient care and improve the healthcare experience.
-
Advancing Patient-Centric Drug Delivery For Neurodegenerative Disease With Orally Dissolving Tablets
Pharmaceutical companies must prioritize patient-centric dosage forms to address challenges like dysphagia, enhance medication compliance, and improve therapeutic outcomes.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
DELIVERED BY DEGRAZIO
-
4 Opportunities For Advancing Drug Delivery
In this article, Fran DeGrazio identifies four prime opportunities for drug delivery developers to move the dial of innovation into 2026 and beyond. These avenues for advancement include diagnostics, patient tolerability, microdosing, and analytical methodologies.

